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ABSTRACT
Delphinidin is a major anthocyanidin compound found in various fruits. It 
has anti-inflammatory, anti-oxidant, and various other biological activities. In this 
study, we identified the epigenetic modulators that mediate the apoptotic effect of 
delphinidin in human prostate cancer cells. We found that treatment of LNCaP cells (a 
p53 wild-type, human prostate cancer cell line) with delphinidin increased caspase-3, 
-7, and -8 activity, whereas it decreased histone deacetylase activity. Among class 
I HDACs, the activity of HDAC3 was specifically inhibited by delphinidin. Moreover, 
the induction of apoptosis by delphinidin was dependent on caspase-mediated 
cleavage of HDAC3, which results in the acetylation and stabilization of p53. We also 
observed that delphinidin potently upregulated pro-apoptotic genes that are positively 
regulated by p53, and downregulated various anti-apoptotic genes. Taken together, 
these results show that delphinidin induces p53-mediated apoptosis by suppressing 
HDAC activity and activating p53 acetylation in human prostate cancer LNCaP cells. 
Therefore, delphinidin may be useful in the prevention of prostate cancer.
INTRODUCTION
Prostate cancer is one the most widespread types 
of cancer. Until recently, it was the most common cancer 
among men in Western countries, whereas its incidence is 
increasing in Asian populations. In the United States alone, 
186,320 new cases of prostate cancer will be diagnosed 
and a total of 28,660 deaths are predicted [1]. Prostate 
cancer is a slowly growing cancer and is usually detected 
at a late stage [2]. Most patients exhibit increased levels 
of specific cancer markers, such as the prostate specific 
antigen (PSA) which is secreted into blood circulation [3]. 
Because prostate cancer is initially androgen-dependent, 
androgen deprivation is commonly used to cause it to 
regress [4]. However, prostate cancers that are not cured 
by surgery eventually become androgen independent, thus 
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resistant to anti-androgen therapy, and progress to highly 
aggressive metastatic cancer often leading to a patient’s 
death [5]. Moreover, standard chemotherapy is rather 
ineffective for prostate cancer and has serious side effects 
due to its toxicity.
An alternative approach is the use of natural dietary 
compounds for either chemoprevention or chemotherapy. 
Two examples are resveratrol and EGCG, found in 
red wine and green tea, respectively. These have been 
demonstrated to be beneficial agents as they interfere 
with key processes involved in cancer development and 
progression. Among polyphenols, a promising dietary 
component is delphinidin (Figure 1A), one of the main 
anthocyanidins. Delphinidin is a diphenylpropane-based, 
polyphenolic ring structure-harboring compound that is 
naturally found in pomegranates, berries, grapes, beets, 
and eggplants [6]. Delphinidin possesses anti-cancer, anti-
inflammatory, and anti-angiogenic properties. Recently 
published reports showed that it is able to inhibit the 
invasion of breast cancer cells [7]. Due to the factors 
mentioned above (emergence of androgen-independent 
prostate cancer cells, low efficiency and serious side 
effects of classic chemotherapy against this type of 
cancer), dietary chemoprevention and dietary therapy of 
prostate cancer are increasingly considered as a promising 
means to reduce the occurrence of this type of cancer, or 
reduce the side effects during its treatment, respectively 
[8, 9].
Figure 1: Delphinidin induces apoptosis in human prostate cancer LNCaP cells. A. The structure of delphinidin. B. The 
cytotoxic effect of delphinidin on human prostate cancer cells, as measured using the MTT assay. Statistical significance was determined 
using Student’s t-test; *P < 0.01 versus LNCaP cells not treated with delphinidin. C. Morphological changes of prostate cancer cells with 
or without delphinidin treatment. Cells were cultured in complete medium for 12 h. D. Dead cells were stained using TUNEL assay kits. 
As the dye is very positively charged, it cannot penetrate non-compromised cell membranes, thus it cannon enter and stain living cells. The 
arrow indicates dead cells. The data are expressed as mean ± SD (standard deviation) for triplicate measurements.
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Histone deacetylases (HDACs) are widely 
expressed, highly conserved proteins. Eighteen human 
HDACs have been identified, which are grouped into 
four classes based on their homology to their respective 
yeast orthologs. Class I HDACs (1, 2, 3, and 8) are 
homologous to the yeast transcriptional regulator RPD3, 
class II HDACs (HDAC 4–7, 9, 10) are similar to Hda1, 
and class III HDACs (SIRTs 1–7) are NAD+-dependent 
histone deacetylases homologous Sir2 [10]. HDAC11 
is quite different from the members of the other classes 
and has been placed in a fourth class. In addition to 
histone proteins, HDACs have many non-histone protein 
substrates, including p53, NF-kB, and STAT, which are 
important transcription factors regulating the expression 
of a large number of genes [11]. HDACs are involved in 
DNA replication, cell cycle progression, gene repression, 
cell proliferation, and tumorigenesis in various cells 
[12]. However, the roles of the various HDACs in cell 
proliferation and cell death are not yet fully established.
HDACs are important therapeutic targets in various 
human cancers, because they regulate the expression 
of p53 and its activation [13–16]. The p53 protein is a 
key transcription factor of tumor cell death signaling 
pathways as it regulates the expression of genes involved 
in apoptosis and cell cycle arrest [17, 18]. Another 
protein, MDM2, binds and ubiquinates p53, resulting in 
the rapid degradation of the latter. However, acetylation 
of p53 by two histone acetyltransferases (HATs), p300 
and CBP, abrogates the ability of mdm2 to bind and 
ubiquinate p53, leading to p53 stabilization [19, 20]. 
As expected, deacetylation of p53 by HDACs has the 
opposite effect, i.e., it promotes its degradation. Among 
HDACs, HDAC3 localizes to the nucleus, cytoplasm, and 
plasma membrane. It is functionally distinct from other 
members of Class I HDACs [21] and exerts an important 
regulatory effect on the expression and function of 
p53. According to recent research, the cleavage of 
HDAC3 that takes place during apoptosis induced by 
chemotherapeutic agents, leads to the expression of p53-
regulated pro-apoptotic genes [22].
In this study, we demonstrate that delphinidin 
induces apoptosis in prostate LNCaP cancer cells by 
inducing caspase-mediated HDAC3 cleavage that results 
in the acetylation and stabilization of p53. The activation 
of effector caspases during delphinidin-induced apoptosis 
is involved in the cleavage and inactivation of HDAC3, 
whereas the downregulation of HDAC3 activity leads 
to the oligomerization of p53 in human prostate cancer 
LNCaP cells. Moreover, delphinidin-induced apoptosis is 
accompanied by the upregulation of pro-apoptotic genes 
such as Bax and p21. To sum up, we demonstrated that 
treatment of LNCaP cells with delphinidin significantly 
enhanced p53 stabilization and p53 acetylation. 
Delphinidin appears to serve as a multifunctional anti-
tumor and HDAC-inhibition agent in various types of 
human cancer.
RESULTS
Delphinidin induces apoptosis in human LNCaP 
prostate cancer cells
Delphinidin, the major anthocyanidin compound 
in pigmented fruits and vegetables, possesses a 
diphenylpropane-based, polyphenolic-ring structure 
and has anti-inflammatory, anti-oxidant, and anti-
angiogenic activity (Figure 1A). Previously published 
reports also suggest that treatment of prostate cancer 
cells with delphinidin results in an efficient, dose-
dependent inhibition of cell growth. Hafeez et al. (2008) 
of the University of Wisconsin observed that whereas 
delphinidin exerts a differential dose response effect on 
the growth of prostate cancer cells, it did not affect the 
viability of normal prostate epithelial cells [6].
To examine the mechanism of delphinidin-induced 
apoptosis, we first examined the cytotoxic effect of 
delphinidin on human prostate cancer cells using a cell 
viability assay. Delphinidin did not affect the viability 
of Du145 or PC3 cells at any of the used concentrations, 
whereas it had a clear dose-dependent cytotoxic effect on 
LNCaP cells. (Figure 1B).
In order to confirm that the aforementioned 
changes in viability were a result of delphinidin-induced 
apoptosis, we microscopically observed and applied the 
TUNEL assay on prostate cancer cell lines after a 12-
hour treatment with 100-μM delphinidin. As shown in 
Figure 1C, delphinidin-treated LNCaP cells displayed 
changes in morphology that relate to apoptosis, whereas 
Du145 and PC3 cells did not exhibit similar changes in 
cellular morphology. The TUNEL assay can be used to 
detect dead or dying cells exhibiting DNA fragmentation, 
which is a sign of apoptosis. After delphinidin-treated cells 
were stained, the dead cells were measured in a multiplex 
microplate reader (Figure 1D). As seen in Figure 1D, 
treatment of LNCaP cells with delphinidin resulted in the 
appearance of labeled dead cells. In contrast, no stained 
cells were detected in delphinidin-treated Du145 and PC3 
cultures. Therefore, both the morphological observations 
and the TUNEL assay results indicate that delphinidin 
induces apoptosis of LNCaP cells. The fact that LNCaP 
cells are wt-p53 positive, while the two unaffected cancer 
cell lines, Du145 or PC3, do not express functional p53, 
suggests that delphinidin induces apoptosis in a p53-
dependent fashion.
Delphinidin induces caspase-dependent 
apoptosis in LNCaP cells
Caspases play a major role in cancer cell apoptosis. 
Caspases-8 and-9 directly or indirectly activate the 
effector caspases-3 and -7, which serve as key factors 
in the apoptosis signaling pathway [23]. To investigate 
the mechanism of delphinidin-induced apoptosis in 
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LNCaP cells, we examined the activation of caspases-3, 
-7, -8, and -9, as well as the cleavage of PARP-1 in the 
cytosol. PARP-1 is a substrate of effector caspases, so 
the presence or absence of the cleaved form is a clear 
indication of whether or not caspases play an essential role 
in delphinidin-induced apoptosis of LNCaP cells. Prostate 
cancer cells were incubated with various concentrations 
of delphinidin (50, 100, and 150 mM) for 24 h, while 
non-treated cells served as controls. In LNCaP cells, 
delphinidin treatment led to an increase in the expression 
of caspases-8 and to higher levels of the cleaved forms of 
caspase-3, caspase-7, and PARP-1, whereas no changes 
were observed in Du145 and PC3 cells (Figure 2A). 
These results clearly suggest that the delphinidin-induced 
apoptosis of LNCaP cells was initiated by caspase-8 
activation. Caspase-8 cleaved caspases-3 and -7 activating 
them. Truly, our experiments showed that delphinidin-
induced apoptosis of LNCaP cells was accompanied by 
a significant increase in caspase activity (Figure 2B). 
In turn, the activated effector caspases cleaved their 
substrate, PARP-1. As a whole, our results suggest that 
delphinidin-induced apoptosis in LNCap is mediated by 
caspase activation.
To confirm the role of the caspase cascade in the 
delphinidin-induced apoptosis of LNCaP cells, we tried 
to inhibit apoptosis by blocking caspase activation 
with a general caspase inhibitor (zVAD). LNCaP cells 
were incubated with 100 μM delphinidin for 24 h, in 
Figure 2: Delphinidin induces caspase-dependent apoptosis in LNCaP cells. A. Delphinidin induced the activation of effector 
caspases. LNCaP cells were treated with delphinidin (100 μM) for 12 h. The expression of caspase-8, caspase-9, and the levels of cleaved 
caspase-3, cleaved caspase-7, and cleaved PARP-1 were activated by delphinidin treatment, as determined by western blot analysis. 
B. Delphinidin increased caspase activity in LNCaP cells. The total caspase activity in prostate cancer cells treated with delphinidin was 
measured. C. Delphinidin-induced apoptosis was suppressed by caspase inhibitor zVAD. LNCaP cells were pretreated for 30 min with 
or without zVAD (40 μM); afterwards, they were treated with delphinidin (100 μM) for 12 h. D. Delphinidin significantly induced the 
activation of caspases in LNCaP cells. LNCaP cells were pretreated for 30 min with zVAD (40 μM) or zDQMD; afterwards, they were 
treated with delphinidin (100 μM) for 12 h. After incubation, the activity of caspase-3/7 was inhibited by zVAD or zDQMD treatment. 
E. The cytotoxicity effect of delphinidin was reduced by caspase inhibitors. Cell viability was measured using the MTT assay. All data are 
expressed as the mean ± SD for triplicate measurements. Statistical significance was determined using Student’s t-test; *P < 0.01 versus 
LNCaP cells that were not treated with delphinidin.
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the presence or absence of zVAD. As shown in Figure 
2C, caspase activation in delphinidin-treated LNCaP 
cells was inhibited by zVAD treatment. We proceeded 
to examine the effect of zVAD, as well as the effect of 
a specific inhibitor of caspases-3 and -7, zDQMD, on 
the delphinidin-induced apoptosis of LNCaP cells. The 
caspase-3/-7 activity analysis showed that the delphinidin-
induced activation of these two caspases was significantly 
inhibited by zDQMD (Figure 2D). To evaluate whether the 
inhibition of caspases-3 and -7 decreases the cytotoxicity 
that is caused by delphinidin treatment, we performed 
another viability assay. The inhibitor effectively blocked 
caspase activity and reduced cytotoxicity. Therefore, the 
inactivation of caspases by zVAD or zDQMD dramatically 
inhibits delphinidin-induced apoptosis in LNCaP cells 
(Figure 2E). Taken together, these results strongly suggest 
that delphinidin promotes apoptosis in these cells by 
activating the effector caspases-3 and -7.
Delphinidin antagonizes HDAC3 activity and 
increases the cytotoxicity of LNCaP cells
Histone modifications regulate the activation 
and stabilization of histones and non-histone proteins. 
HATs and HDACs dynamically regulate chromatin 
remodeling, histone modification, and gene expression. 
The main function of HDACs is the repression of gene 
transcription via deacetylation of lysine residues in 
histones or non-histones [24]. HDAC3 is known to 
regulate the transcription of genes through its effect on 
chromatin conformation [25, 26], and its functions have 
been demonstrated in many research studies. Recently, we 
reported the existence of three novel HDAC3-interacting 
partners, L3MBTL1, CREB3, and PDCD5, and described 
roles of HDAC3 in epigenetic regulation mediated by 
these proteins [27]. It is our belief that HDAC3 is an 
important regulatory factor of proliferation, growth 
homeostasis, and apoptosis of cancer cells during various 
cellular events.
To determine whether the mechanism through which 
delphinidin induces apoptosis in LNCaP cells includes 
downregulation of HDAC3 activity; we measured total 
HDAC activity in cells treated with delphinidin. HDAC 
activity was decreased by delphinidin in both PC3 cells 
and LNCaP cells. However, the reduction was much 
greater in LNCaP cells. (Figure 3A). We then examined 
whether delphinidin is a global or a specific HDAC 
inhibitor. As seen in Figure 3B, delphinidin reduced the 
activity of HDAC3 activity to a greater extent compared 
to the activity of the other class I HDACs. We concluded 
that delphinidin induced apoptosis of LNCaP cells via 
the specific inhibition of HDAC3 activity. To examine 
the mechanism through which the reduction of HDAC3 
activity takes place, we determined the protein levels 
of class I HDACs and PARP-1 in delphinidin-treated 
cancer cells using western blot analysis. As shown in 
Figure 3C, delphinidin treatment dramatically reduced 
HDAC3 expression and induced PARP-1 cleavage 
in a dose-dependent manner. These data suggest that 
delphinidin induces apoptosis in LNCaP cells through 
the suppression of HDAC3 expression and deacetylase 
activity. To confirm that the suppression of HDAC activity 
leads to apoptosis, we examined the viability of LNCaP 
cells that were incubated with 100 μM delphinidin alone, 
or together with either TSA, a general HDAC inhibitor, 
or MS-275, a specific HDAC1/3 inhibitor. As expected, 
in both cases of co-treatment the viability of LNCaP cells 
was lower compared to the viability of cells treated with 
delphinidin alone. We also examined whether knocking 
down HDAC3 using siRNA enhanced the apoptotic effect 
of delphinidin in LNCaP cells. As shown in Figure 3D, 
HDAC3-knocked down cells treated with delphinidin 
displayed a significantly lower viability compared to 
normally expressing HDAC3 cells treated with delphinidin 
alone or co-treated with delphinidin and HDAC inhibitors. 
Thus, HDAC3 RNAi-mediated knockdown can enhance 
the apoptotic effect of delphinidin on LNCaP cells. Taken 
together, our findings reveal that HDAC3 is a critical 
factor in delphinidin-induced apoptosis in human prostate 
cancer LNCaP cells.
Delphinidin-induced HDAC3 cleavage leads to 
p53 acetylation in LNCaP cells
Various studies have reported that LNCaP cells 
harbor two functional alleles encoding wild-type p53, 
whereas DU145 cells express a modified p53 protein 
with two point mutations (Phe223Leu and Val274Phe) 
and PC3 cells are deficient in functional p53 protein 
production. To further support the finding that delphinidin-
induced apoptosis is mediated by a downregulation 
of HDAC3 expression and activity, we examined the 
effects of different concentrations of delphinidin on 
p53 acetylation. According to previous reports [28, 29], 
HDAC3 is cleaved because of sorbitol-induced caspase-7 
activation, or during FasL-mediated apoptosis. As p53 is 
one of the targets of the deacetylases activity of HDAC3, 
the cleavage of HDAC3 during apoptosis results in an 
increase in p53 acetylation, whereas the transcription of 
pro-apoptotic genes is activated. Based on these reports, 
we proceeded to examine whether an increase in p53 
acetylation due to HDAC3 cleavage is also taking place in 
delphinidin-induced apoptosis. LNCaP cells and DU145 
cells treated with delphinidin (50 and 100 mM), as well 
as untreated controls, were examined using western blot 
analysis. The apoptotic effect of delphinidin in LNCaP 
cells was accompanied by cleavage of both PARP-1 and 
HDAC3 (Figure 4A). The cleaved form of HDAC3 can 
be detected using an anti-HDAC3 antibody raised against 
the N-terminal region of anti-HDAC3, whereas antibodies 
recognizing the C-terminal region are not able to bind to 
cleaved HDAC3.
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We then determined whether p53 acetylation and 
stability were enhanced by HDAC3 cleavage during 
delphinidin-induced apoptosis. LNCaP cells were treated 
with different doses of delphinidin for 24 h. As shown 
in Figure 4B, delphinidin increased p53 acetylation and 
stability, whereas HDAC3 was cleaved by activated 
caspase-7 in delphinidin-treated LNCaP cells, in which 
apoptosis was induced. We also examined the effect of two 
other anthocyanidins, cyanidin and aurantinidin, on the 
p53 acetylation status. As shown in Figure 4C, delphinidin 
increased p53 acetylation and stability to a greater extent 
compared to that by cyanidin and aurantinidin.
To demonstrate that endogenous p53 is stabilized 
for activation in response to delphinidin, p53 was 
immunoprecipitated from lysates of LNCaP cells treated 
with delphinidin and/or glutaraldehyde (a protein-protein 
crossinker). Proteins were immunoprecipitated for 20 min 
at 37°C and detected by western blot analysis using an 
anti-p53 antibody. These results show that the stabilization 
and activation of p53 were induced by enhancing the 
oligomerization of p53 (Figure 4D), whereas it is known 
that oligomerization of p53 is essential for enhancing p53 
activity for DNA binding, protein-protein interactions, post-
translational modification, and stabilization [30]. As a whole, 
these findings suggest that delphinidin induced p53-mediated 
apoptosis in LNCaP cells through p53 oligomerization.
Delphinidin-induced apoptosis of LNCaP cells is 
mediated by activation of p53 and inactivation of 
HDAC3
According to recent reports, p53-dependent 
apoptosis of cancer cells is regulated by post-translational 
modification of p53, including acetylation. Therefore, 
Figure 3: HDAC3 activity was downregulated during delphinidin-induced apoptosis in LNCaP cells. A. Delphinidin 
reduces total HDAC activity. Prostate cancer cells were treated with various concentrations of delphinidin (50, 100, and 150 μM) for 
24 h. Non-treated cells were used as controls. Statistical significance was determined using Student’s t-test; *P < 0.01 versus controls. 
B. Delphinidin inhibits HDAC3 activity. HDAC activity assays were performed using a colorimetric HDAC activity assay kit. The data are 
expressed as mean ± SD for triplicate measurements. Statistical significance was determined using Student’s t-test; *P < 0.05 versus non-
treated controls. C. HDAC3 expression was reduced by delphinidin treatment. LNCaP cells were treated with delphinidin. Cell lysates were 
processed for western blot analysis using the indicated antibodies. D. The viability of LNCaP cells was decreased by HDAC inhibitors and 
HDAC3 siRNA. LNCaP cells were treated with delphinidin and TSA (MS-275 or HDAC3 siRNA) for 12 h. The cell viability was measured 
using the MTT assay. All data are expressed as the mean ± SD for triplicates. Statistical significance was determined using Student’s t-test; 
*P < 0.01 versus LNCaP cells that were not treated with delphinidin.
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we examined the results of knocking down HDAC1 or 
HDAC3 on the stability of p53, on the p53 acetylation 
levels, as well as on the expression of the pro-apoptotic 
proteins p21 and BAX (which is regulated by p53), in 
delphinidin-treated LNCaP cells. Treatment of LNCaP 
cells with delphinidin and si-HDAC1 or si-HDAC3 
increased total p53 and acetylated-p53 protein levels, as 
well as the expression of p21 and BAX proteins, whereas 
the increase was greater when HDAC3 was knocked 
down (Figure 5A). We also performed a cell viability 
assay, where treatment of LNCaP cells with si-HDAC3 
and delphinidin led to increased cytotoxicity. We conclude 
that HDAC3 inhibition enhances the apoptotic effect of 
delphinidin in LNCaP cells.
To demonstrate that endogenous p53 undergoes 
oligomerization in delphinidin-treated cells, p53 was 
immunoprecipitated from cell lysates of LNCaP cells 
treated with delphinidin and/or si-HDAC3, and visualized 
using western blot analysis. As seen in Figure 5C, p53 
oligomerization was increased in delphinidin-treated 
LNCaP HDAC3 knockdown cells, compared to the 
delphinidin-treated cells whose HDAC3 expression had 
not been reduced by si-RNA treatment. We conclude that 
HDAC3 is directly involved in p53-dependent apoptosis. 
To further study the effect of HDAC3 on p53 stability in 
the presence of delphinidin, we overexpressed Flag-fused 
proteins containing wild-type HDAC3, or a point-mutation 
of the protein (HDAC3D309A), or a C-terminal deletion 
mutant (HDAC3ΔC). Overexpression of wild-type HDAC3 
and HDAC3D309A inhibited the ability of delphinidin to 
induce acetylation and stabilization of p53. The expression 
of p21 and BAX proteins was reduced (Figure 5D) and the 
cells became resistant to delphinidin-induced cytotoxicity 
(Figure 5E). In contrast, overexpression of HDAC3ΔC did 
not inhibit the effects of delphinidin on p53 levels, p53 
acetylation, p21 and BAX expression, or cytotoxicity 
Figure 4: HDAC3 cleavage induces p53 acetylation and oligomerization. A. HDAC3 was cleaved because of delphinidin 
treatment. LNCaP cells were treated with delphinidin (100 μM). HDAC3 cleavage was then detected by western blot analysis using the 
indicated HDAC3 antibody. B. Delphinidin induced p53 acetylation through HDAC3 inactivation. Delphinidin–treated LNCaP cell lysates 
were analyzed by western blot analysis using the indicated antibodies. C. Delphinidin induced hyperacetylation of p53, and anthocyanidins 
upregulated p53 expression. D. Delphinidin induced p53 multimerization. Delphinidin-treated LNCaP cells were extracted using lysis 
buffer, and cell extracts were incubated with glutaraldehyde for 20 min at 37 °C. Samples underwent western blot analysis using an anti-p53 
antibody.
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(Figure 5D, Figure 5E). We next examined whether the 
p53 oligomerization caused by delphinidin is negatively 
regulated by HDAC3. As shown in Figure 5F, HDAC3 
overexpression is able to inhibit the oligomerization of 
p53 in delphinine-treated LNCaP cells.
Delphinidin-induced HDAC3 downregulation 
leads LNCaP cells to apoptosis via the activation 
of p53 target genes
Recent studies have demonstrated that the cleavage 
of HDAC3 in the apoptotic signaling pathway enhances 
the expression of p53-regulated pro-apoptotic genes [22, 
29]. To examine the activation of the transcription of 
p53 target genes because of delphinidin treatment, we 
created reporter plasmids consisting of the promoters 
of three genes, p21, Bax, and Noxa, and the coding 
sequence of luciferase. The promoters of these three 
genes contain p53 binding elements and are activated 
by p53. We transiently transfected LNCaP cells with the 
reporter plasmids and treated the cells with delphinidin 
for 24 h. As shown in Figure 6A, delphinidin treatment 
led to the activation of all three promoters. We conclude 
that delphinidin-induced apoptosis in LNCaP cells is 
accompanied by the transcriptional activation of p53-
upregulated pro-apoptotic genes. We next examined the 
Figure 5: The silencing or C-terminal mutation of HDAC3 activates the expression of p21 and BAX by inducing 
oligomerization of p53. A. HDAC3 silencing increased expression of BAX and p21 in delphinidin–treated LNCaP cells. HDAC3 
siRNA was transfected into LNCaP cells with delphinidin. B. Co-treatment with delphinidin and HDAC3 siRNA reduced cell viability, 
which was measured using the MTT assay. All data are expressed as the mean ± SD for triplicate measurements. Statistical significance 
was determined using Student’s t-test; *P < 0.01 versus HDAC3 siRNA-treated LNCaP cells. C. HDAC3 silencing enhanced p53 
oligomerization. D, E. HDAC3wt and HDAC3D391A inhibited cell viability during delphinidin-mediated apoptosis. D. Delphinidin–treated 
LNCaP cell extracts were analyzed by western blot analysis using the indicated antibodies. E. The cell viability was measured using the 
MTT assay. All data are expressed as the mean ± SD for triplicates. Statistical significance was determined using Student’s t-test; *P < 0.01 
versus delphinidin-treated LNCaP cells. F. HDAC3 over-expression inhibited p53 oligomerization.
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role of HDAC3 in the expression of pro-apoptotic genes. 
HDAC3 knockdown dramatically enhanced the expression 
of p53 and the pro-apoptotic genes Bax, p21, Puma, and 
Noxa. HDAC1 knockdown did not have a similar effect 
on the expression of these genes (Figure 6B). We also 
performed experiments where wild-type and mutant forms 
of HDAC3 were overexpressed. As shown in Figure 6C, 
overexpressing of HDAC3wt and HDAC3D391A suppressed 
the delphinidin-induced transcription of pro-apoptotic 
genes, whereas HDAC3ΔC did not affect the transcription 
of these genes. Therefore, our results demonstrate that 
HDAC3 is cleaved by effector-caspases in response to 
delphinidin-initiated cell death signaling, resulting in the 
transcriptional activation of pro-apoptotic target genes, 
including Puma, Bax, and Noxa. As shown in Figure 6D, 
delphinidin treatment of LNCaP cells results in activation 
of effector caspases, whereas activated caspase-3 cleaves 
HDAC3. These results suggest that HDAC3 cleavage 
leads to the hyperacetylation and oligomerization of p53, 
as well as to the transcriptional activation of p53 target 
genes during delphinidin-induced apoptosis in p53 wild-
type human prostate cancer cells.
Figure 6: HDAC3 regulates the expression of p53 target genes. A. Delphinidin increases the transcriptional activity of p53 target 
genes. LNCaP cells were transiently co-transfected with reporter constructs p21-Luc, Bax-Luc, or Noxa-Luc, and with pSV40 plasmids. 
After delphinidin treatment, cells were harvested and extracted, and dual luciferase activity was measured. Reporter activities were 
normalized relative to Renilla luciferase activities and were expressed as mean ± SD for triplicate measurements. Statistical significance 
was determined using Student’s t-test; *P < 0.01 versus LNCaP cells that had not been treated with delphinidin. B. Knock-down of HDAC3 
with delphinidin treatment enhances the expression of p53 target genes. Statistical significance was determined using Student’s t-test; 
*P < 0.01 versus delphinidin-treated LNCaP cells. C. Over-expression of HDAC3 represses the expression of p53 target genes, but not 
expression of HDAC3ΔC. The expression level of each gene was analyzed by qRT-PCR using the total mRNA from LNCaP cells treated 
with delphinidin and with/without HDAC3. The data are expressed as the mean ± SD for triplicate measurements. Statistical significance 
was determined using Student’s t-test; *P < 0.01 versus delphinidin-treated LNCaP cells. D. A model based on our findings. Treatment 
with delphinidin increases the expression of active caspases in LNCaP cells. The active caspases then induce HDAC3 cleavage, resulting 
in p53 acetylation, activation, and oligomerization. Importantly, delphinidin accelerates the hyperacetylation of p53 in order to activate 
p53-related apoptosis markers after HDAC3 inactivation by caspase activation.
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DISCUSSION
Prostate cancer is the second most common type of 
cancer in men worldwide and its incidence is continuously 
increasing. Recently, a worldwide pharmaceutical 
company started to develop novel plant-based natural 
compounds for the prevention and treatment of prostate 
cancer [6, 31].
Anthocyanidins are flavonoid polyphenols that are 
abundant in fruits and vegetables [32]. Several published 
studies have demonstrated the potential of flavonoids 
as anti-tumor chemopreventive and chemotherapeutic 
agents. Flavonoids have also been associated with 
beneficial effects in the treatment of diabetic retinopathy, 
atherosclerosis, and various microvascular diseases, 
which are attributed to their potential anti-inflammatory 
properties [32]. Delphinidin is an anthocyanidins with 
potent anti-oxidant, anti-inflammatory, and anti-cancer 
properties. It may aid in the development of mechanism-
based cancer-prevention approaches [33].
In this study, we demonstrated the chemotherapeutic 
effects of delphinidin by studying its pro-apoptotic effect 
on human prostate cancer cells. Treatment of LNCaP 
cells with delphinidin reduced cell viability (Figure 1) by 
inducing apoptosis (Figure 2). Delphinidin treatment led 
to the activation of initiator caspases and effector caspases, 
and resulted in the cleavage of PARP-1 and HDAC3 
in LNCaP cells (Figure 3), as well as in a significant 
increase in the expression of the pro-apoptotic proteins 
Bax, PUMA, and p21 (Figure 6). Our results also show 
that the stability of p53 determines the fate of cancer 
cells in patients being treated with delphinidin or with a 
combination of delphinidin and other agents.
HDACs are transcriptional co-repressors that 
regulate cell cycle arrest, cell differentiation, and 
apoptosis in cancer cell lines [34]. Inhibition of HDACs 
has been shown to enhance tumorigenesis in a variety of 
cancer cell types [35]. Clinical trials of HDAC inhibitors 
for the treatment of both hematopoietic and solid tumors 
are currently underway [36]. HDACs have a physiological 
role in the maintenance of cell proliferation, cell survival, 
and the suppression of intestinal and epithelial cell 
maturation. Therefore, treatment with HDAC inhibitors 
induces growth arrest, maturation, and apoptosis of cancer 
cell lines. Among HDACs, HDAC1 and HDAC2 have 
been demonstrated to play a role in repressing intestinal 
cell maturation and promoting cell proliferation and 
survival [37, 38]. In this study, we investigated the role 
of HDAC3 in cell survival and apoptosis; we observed 
increased apoptotic rates in HDAC3 knockdown LNCaP 
cells treated with delphinidin. We also demonstrated that 
HDAC3 cleavage in delphinidin-induced apoptosis results 
in the p53-dependent activation of the expression of p21 
and Bax, whereas overexpression of HDAC3 significantly 
reduced the delphinidin-induced activation of the p21, 
Bax, and Noxa promoters. Conversely, knockdown of 
HDAC3 enhanced the activating effect of delphinidin on 
these promoters. Moreover, HDAC3 cleavage reduced cell 
growth and cell survival, and mediated the dose-dependent 
apoptotic effect of delphinidin.
The p53 protein is very important for the regulation 
of viability and genomic stability of cancer cells [39], 
because it activates major pro-apoptotic genes; therefore, 
mutations of p53 have been reported in a variety of 
human cancers. The ability of p53 to exert its function 
is efficiently regulated by specific modifications, cellular 
localization, and cell-cycle phase [40]. Acetylation of 
lysine residues in the p53 C-terminus has been shown 
to block its interaction with MDM2, inhibiting its 
ubiquitination and degradation. Therefore, acetylation 
of p53 is a key regulatory factor for p53 stability and 
activity during cancer cell apoptosis. Acetylation of p53 
takes place at specific lysine residues and is carried out 
by acetyltransferases such as p300 and CBP. The status 
of acetylated p53 is known to be regulated by various 
HDACs [41]. Indeed, deacetylation of p53 by HDAC3 
is required for repressing the hyperacetylation of p53 
during the apoptosis of cancer cells. In this study, we 
have demonstrated that the inactivation of HDAC3 
increases the levels of p53 acetylation, its stability 
and causes its oligomerization, leading to apoptosis. 
Our data suggests that delphinidin treatment leads to 
caspase-mediated HDAC3 cleavage, resulting in the 
hyperacetylation of p53.
To sum up, we investigated the apoptotic effect of 
delphinidin on prostate cancer cells and demonstrated that 
the delphinidin-induced apoptosis is achieved through 
the activation of p53. Caspases have been shown to be 
involved in the induction of apoptosis by delphinidin. 
Indeed, our results show that the inactivation and cleavage 
of HDAC3 is a result of the activation of effector caspases. 
We also ascertained that delphinidin-induced apoptosis 
could be blocked by inhibiting HDAC3 cleavage with 
specific caspase-3/-7 inhibitors. Our results strongly 
suggest that delphinidin, as well as other HDAC inhibitors, 
should be considered as potential agents for the treatment 
of human prostate cancer.
MATERIALS AND METHODS
Cell culture and reagents
The human prostate cancer cell lines LNCaP, 
PC3, and DU145, were obtained from the American 
Type Culture Collection and were cultured in RPMI 
supplemented with 10% fetal bovine serum (FBS) and 
1% antibiotics-antimycotics in a humidified 5% CO2 
atmosphere at 37 °C. Cells were treated with delphinidin 
(Sigma-Aldrich, St. Louis, MD, USA). RPMI, antibiotics-
antimycotics, FBS, and the Lipofectamine 2000 
transfection reagent were purchased from Thermo-Fischer 
Scientific (Waltham, MA, USA).
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Cell viability assay
Cell viability was determined using the conventional 
MTT reduction assay. Briefly, 5 × 103 – 1 × 104 cells 
were seeded per well in 96-well plates. After a 12-
hour incubation, cells were incubated with or without 
delphinidin (50, 100, or 150 mM) for another 24 h. 
Afterwards, cells were treated with 15 mL of MTT 
solution (2 mg/mL) for 90 min at 37 °C. The absorbance 
was measured at 570 nm in a Model 550 micro plate 
reader (BIO-RAD Laboratories, Hercules, CA, USA), 
whereas a reference wavelength of 630 nm was used. 
All results of MTT assays are presented as the means (± 
standard deviation) of three independent experiments.
RNAi experiments
The siRNAs used in this study were purchased 
from Bioneer Corporation (Daejeon, Korea), and 
had the following sequences: HDAC1 siRNA, 
5′-GAGUCAAAACAGAGGAUGA-3′; HDAC3 siRNA, 
5′-GAGCUUCAAUAUCCCUCUA-3′. After a 12-hour 
incubation of LNCaP cells in RPMI not containing 
FBS or antibiotics, transfection was carried out using 
Lipofectamine 2000 with 100 pmol non-specific siRNA, 
HDAC1 siRNA, or HDAC3 siRNA, according to the 
manufacturer’s instructions. After 4 h, the medium was 
changed and cells were incubated for another 2 days.
TUNEL assay
TUNEL assay was performed using the HT Titer 
TACS Assay Kit (Trevigen, Gaithersburg, MD, USA) 
according to the manufacturer’s instructions. LNCaP cells 
were fixed with 3.7% buffered formaldehyde solution for 5 
min and washed with PBS. Cells were then permeabilized 
in 100% methanol for 20 min, washed twice with PBS, 
digested with proteinase K for 15 min, quenched with 
3% hydrogen peroxide, washed with distilled water, 
labeled and incubated with deoxynucleotidyl transferase 
at 37 °C for 90 min, and then treated with stop buffer. 
Afterwards, cells were incubated in the presence of TACS-
Sapphire substrate for 30 min. The colorimetric reaction 
was stopped with 0.2 N HCl and measured in a multiplex 
microplate reader at 450 nm absorbance.
Caspase activity assay
Delphinidin-induced caspase activation was 
evaluated using Caspase-Glo -3/-7 and total caspase 
kits (Promega, Madison, WI, USA) according to the 
manufacturer’s instructions. Briefly, LNCaP, PC3, and 
DU145 cells (4,000 cells per well in 100 μL media) were 
plated in 96-well, white-walled, clear-bottom plates 
(Lonza, Basel, Switzerland). The cells were then treated 
with delphinidin. After 24 h, 100 μL of assay reagent was 
added to each well. The plate was incubated in the dark for 
60 min, and afterwards the luminescence was measured 
using a SpectraMAX 250 Optima plate reader (Molecular 
Devices, Sunnyvale, CA, USA).
HDAC activity assays
The histone deacetylase (HDAC) activity assay was 
carried out using a commercially available kit (Biovision, 
San Franscisco, CA, USA) according to the manufacturer’s 
instructions. In order to perform activity assays for 
specific HDACs, HDAC1, HDAC2, HDAC3, and HDAC8 
proteins were first immunoprecipitated using anti-HDAC1, 
anti-HDAC2, anti-HDAC3, and anti-HDAC8 from LNCaP 
nuclear extracts. Immunoprecipitated complexes were 
collected and washed with HDAC assay buffer (50 mM 
Tris pH 8.0, 10% glycerol, 0.1 mM EDTA).
Western blot analysis
After a 12-hour treatment with delphinidin, prostate 
cancer cells were washed with cold PBS, scraped off, 
and harvested. Cell extracts were prepared with lysis 
buffer (50 mM Tris-Cl pH 7.5, 150 mM sodium chloride, 
1% NP40, 10 mM sodium fluoride, 10 mM sodium 
pyrophosphate, and protease inhibitors just before use) and 
incubated for 30 min on ice. The lysates were centrifuged 
at 20,000 × g for 10 min at 4 °C. Cell lysate proteins were 
separated by SDS-PAGE using 8% and 12% gels, and then 
transferred to nitrocellulose membranes. The membranes 
were blocked by incubating them for 2 h in 5% w/v non-fat 
milk in PBST. Blocked membranes were incubated with 
the primary antibody for 2 h or overnight at 4 °C. After 
washing with 1X PBST, the membranes were incubated 
with the secondary HRP-conjugated antibody for 1 h. The 
membranes were then subjected to western blot analysis 
and were visualized in the developer apparatus. The 
antibody against HDAC3 (N-terminal detection antibody) 
was manufactured by ATgen (Seongnam, Korea). 
HDAC1, HDAC2, HDA3, HDAC8, caspase-3, caspase-7, 
caspase-8, caspase-9, p53, p21, BAX, and PARP-1 
antibodies were purchased from Santa Cruz Biotechnology 
(Dallas, TX, USA). Acetylated-p53 (Lys373) antibody was 
purchased from Merck Millipore (Darmstadt, Germany). 
Flag and β-actin antibodies were purchased from Sigma-
Aldrich. Secondary anti-mouse and anti-rabbit antibodies 
were purchased from Pierce (Rockford, IL, USA).
RNA extraction and quantitative reverse 
transcription-PCR
Total RNA was isolated with the RNA Easy-spin 
kit (Intron, Korea) according to the manufacturer’s 
instructions, and reverse transcribed with random 
primers using the StrataScript reverse transcriptase 
kit (Stratagene, La Jolla, CA, USA) according to 
the manufacturer’s protocol. All samples were 
normalized to GAPDH and expressed as fold 
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changes. All reactions were done in triplicate. The 
relative expression levels and standard deviations 
were calculated using the comparative quantification 
method. The primers used were the following: 
p53, 5′- CCCAAGCAATGGATGATTTGA-3′ and 
5′-GGCATTCTGGGAGCTTCATCT-3′; p21, 5′- GTGG 
AGAGCATTCCATCCCT-3′ and 5′- TGGATGCAGCT 
TCCTCTCTG-3′; PUMA, 5′-ACTGTGAATCC 
TGTGCTCTGCC-3′ and 5′- CAAATGAATGCCA 
GTGGTCACAC-3′; Bax, 5′- TCTACTTTGCCAGCAA 
ACTGGTGC-3′ and 5′- TGTCCAGCCCATGATGGTT 
CTGAT-3′; Noxa, 5′- CCGTGTGTAGTTGGCATCTC-3′ 
and 5′-CCCACTCAGCGACAGAGC-3′.
Reporter assays
In order to determine the transcriptional activity of 
the promoters of p21, Bax, and Noxa, LNCaP cells were 
transiently co-transfected with pSV40 and one of three 
reporter constructs (p21-Luc, Bax-Luc, or Noxa-Luc) 
The Renilla luciferase reporter plasmid was included 
as an internal control. Cells were harvested, total cell 
extracts were prepared, and dual luciferase activity was 
measured according to the manufacturer’s instructions 
(Promega). All reporter activities were normalized to 
Renilla luciferase activity and are presented as the mean 
(± standard deviation) of three independent experiments.
p53 protein crosslinking assay
The stability of endogenous p53 was measured in 
LNCaP cells undergoing delphinidin-induced apoptosis. Cells 
were prepared with lysis buffer (50 mM Tris-Cl (pH 7.5), 150 
mM sodium chloride, 1% NP40, 10 mM sodium fluoride, 
10 mM sodium pyrophosphate, and protease inhibitors just 
before use) and were then incubated for 30 min on ice. For 
immunoprecipitation, after treatment with delphinidin for 24 
h, LNCaP cells were washed and harvested with cold PBS. 
Cell lysates were prepared with lysis buffer (50 mM Tris-
Cl (pH 7.5), 150 mM sodium chloride, 1% NP40, 10 mM 
sodium fluoride, 10 mM sodium pyrophosphate, and protease 
inhibitors) for 30 min on ice, and then centrifuged at 13,000 
rpm for 10 min at 4 °C. The total cell lysate protein was 
incubated with anti-p53 (DO-1) (Santa Cruz Biotechnology) 
and 20 μL of protein A/G agarose for 2 h at 4°C. After 
washing three times with agarose bead washing buffer, 
glutaraldehyde (Sigma-Aldrich) was added to end up with 
three different conditions: no glutaraldehyde; glutaraldehyde 
at a final concentrations of 0.002%; and glutaraldehyde at a 
final concentration of 0.004%. After incubating for 20 min at 
37 °C, the crosslinking reaction was terminated by adding 2X 
loading buffer. The samples were then heated at 100 °C for 5 
min, separated by SDS-PAGE on 8% gels, and transferred to 
nitrocellulose membranes [30, 42]. The blocked membranes 
were incubated with anti-p53 antibody at 4 °C for 2 h. The 
membranes were then subjected to western blot analysis and 
visualized in the developer apparatus.
Statistical analysis
Statistical analysis was performed using Student’s 
t-test and the SPSS software (SPSS Inc., Chicago, IL, 
USA). A statistical threshold of P < 0.05 was considered 
statistically significant.
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